GuidelineClinical pharmacology and therapeutics2014
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype.
Guideline in Clinical pharmacology and therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 76 citations in OpenAlex.
- Efficacy of personal pharmacogenomic testing as an educational tool in the pharmacy curriculum: A nonblinded, randomized controlled trial.Clinical and translational science · 2021Trial
- Use of Drugs With Actionable Pharmacogenetic Biomarkers and Possible Prescribing Changes Among Older People.Journal of the American Geriatrics Society · 2025Article
- Expanding biobank pharmacogenomics through machine learning calls of structural variation.Genetics · 2025Article
- StarPhase: Comprehensive Phase-Aware Pharmacogenomic Diplotyper for Long-Read Sequencing Data.bioRxiv : the preprint server for biology · 2024Article
- Pharmacogenetic analysis of structural variation in the 1000 genomes project using whole genome sequences.Scientific reports · 2024Article
- Injectable long-acting ivacaftor-loaded poly (lactide-co-glycolide) microparticle formulations for the treatment of cystic fibrosis: In vitro characterization and in vivo pharmacokinetics in mice.International journal of pharmaceutics · 2024Article
- Frequencies of pharmacogenomic alleles across biogeographic groups in a large-scale biobank.American journal of human genetics · 2023Article
- Implementation of Pharmacogenetics in First-Line Care: Evaluation of Its Use by General Practitioners.Genes · 2023Article
- PAnno: A pharmacogenomics annotation tool for clinical genomic testing.Frontiers in pharmacology · 2023Article
- Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines.Frontiers in pharmacology · 2020Review
- The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later.Clinical pharmacology and therapeutics · 2020Review
- Pharmacogenomic Testing: Clinical Evidence and Implementation Challenges.Journal of personalized medicine · 2019Review
- ATP-Binding Cassette Transporters in the Clinical Implementation of Pharmacogenetics.Journal of personalized medicine · 2018Review
- Genetic Testing in Clinical Settings.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2018Review
- A Proteomic Variant Approach (ProVarA) for Personalized Medicine of Inherited and Somatic Disease.Journal of molecular biology · 2018Article
- Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group.Clinical pharmacology and therapeutics · 2018Review
- Phenotypic profiling of CFTR modulators in patient-derived respiratory epithelia.NPJ genomic medicine · 2017Article
- Pharmacogenetic Biomarkers to Predict Treatment Response in Multiple Sclerosis: Current and Future Perspectives.Multiple sclerosis international · 2017Review
- Evidence and resources to implement pharmacogenetic knowledge for precision medicine.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2016Review
- Integrating pharmacogenomics into electronic health records with clinical decision support.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
Abstract
Cystic fibrosis (CF) is a life-shortening disease arising as a consequence of mutations within the CFTR gene. Novel therapeutics for CF are emerging that target CF transmembrane conductance regulator protein (CFTR) defects resulting from specific CFTR variants. Ivacaftor is a drug that potentiates CFTR gating function and is specifically indicated for CF patients with a particular CFTR variant, G551D-CFTR (rs75527207). Here, we provide therapeutic recommendations for ivacaftor based on preemptive CFTR genotype results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.